Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand
European Pregnancy and Paediatric Infections Cohort Collabor, Intira Jeannie Collins(University College London), Lindsay C Thompson(MRC Clinical Trials Unit at UCL), Lino Marques(Institute for Systems Engineering and Computers), Pagakrong Lumbiganon(Khon Kaen University), Carlo Giaquinto(University of Padua), Lars Navér(Karolinska University Hospital), Claire Thorne(University College London), Christoph Königs(Goethe University Frankfurt), Thanyawee Puthanakit(Chulalongkorn University), Gonzague Jourdain(Institut de Recherche pour le Développement), Elizabeth Chappell(MRC Clinical Trials Unit at UCL), Ali Judd(PENTA Foundation), Christian R. Kahlert(Ostschweizer Kinderspital), Antoni Noguera‐Julián(Hospital Sant Joan de Déu Barcelona), Tessa Goetghebuer(Centre Hospitalier Universitaire de Saint-Pierre), Luminiţa Ene(Spitalul Clinic Dr. Victor Babes), Pope Kosalaraksa(Khon Kaen University), Alex Lyons(MRC Clinical Trials Unit at UCL), Filipa Prata(Hospital de Santa Maria), José Tomás Ramos(Universidad Complutense de Madrid), Liubov Okhonskaia(Ministry of Health of the Russian Federation), Luisa Galli(Meyer Children's Hospital), Evgeny Voronin(Ministry of Health of the Russian Federation), Marissa Navarro(Universidad Complutense de Madrid), Anna Turkova(Great Ormond Street Hospital), Anna Samarina, Magdalena Marczyńska(Medical University of Warsaw)
Cited by 5
Related Papers
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
|The Lancet|2007|570
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
|The Lancet|2011|420
Newborns Develop a Th1-Type Immune Response to <i>Mycobacterium bovis</i> Bacillus Calmette-Guerin Vaccination
|The Journal of Immunology|1999|405